Brazilian Protocol for Sexually Transmitted Infections 2020: human T cell lymphotropic virus (HTLV) infection

Imagem de Miniatura
Arquivos
art_ROSADAS_Brazilian_Protocol_for_Sexually_Transmitted_Infections_2020_human_2021_spa.PDF (494.68 KB)
art_ROSADAS_Brazilian_Protocol_for_Sexually_Transmitted_Infections_2020_human_2021_por.PDF (505.9 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2021
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MINISTERIO DA SAUDE
Autores
ROSADAS, Carolina
BRITES, Carlos
ARAKAKI-SANCHEZ, Denise
ISHAK, Ricardo
Citação
EPIDEMIOLOGIA E SERVICOS DE SAUDE, v.30, n.1, Special Issue, article ID e2020605, 24p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
This manuscript is related to the chapter about human T-cell lymphotropic virus (HTLV) that is part of the Clinical Protocol and Therapeutic Guidelines for Comprehensive Care for People with Sexually Transmitted Infections, published by the Brazilian Health Ministry. HTLV-1/2 infection is a worldwide public health problem and Brazil has the largest number of individuals living with the virus. HTLV-1 causes a variety of clinical manifestations of a neoplastic nature, such as adult leukemia/T-cell lymphoma, and also of an inflammatory nature, such as HTLV-1-associated myelopathy, as well as other manifestations such as uveitis, arthritis and infective dermatitis. These pathologies have high morbidity and mortality and negatively impact the quality of life of infected individuals. This review includes relevant information for health service managers and workers regarding virus transmission modes, diagnosis, treatment and monitoring of individuals living with HTLV-1 and 2 in Brazil.
O artigo aborda a infecção pelo vírus linfotrópico de células T humanas (human T lymphotropic virus, HTLV), tema contemplado no Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis, publicado pelo Ministério da Saúde do Brasil. A infecção pelo HTLV-1/2 é um problema de saúde pública mundial, sendo o Brasil o país a referir o maior número de indivíduos convivendo com o vírus. O HTLV-1 causa diversas manifestações clínicas, de natureza neoplásica, como a leucemia/linfoma de células T do adulto, e de natureza inflamatória, a exemplo da mielopatia associada ao HTLV-1 e outras alterações, como uveíte, artrite e dermatite infecciosa. Estas patologias apresentam elevada morbimortalidade e impactam negativamente a qualidade de vida dos indivíduos infectados. A presente revisão inclui informações relevantes para gestores e profissionais de saúde sobre os mecanismos de transmissão viral, diagnóstico, tratamento e acompanhamento de indivíduos vivendo com o HTLV-1/2 no Brasil.
El artículo está relacionado con el capítulo sobre virus linfotrópico de células T humanas (human T lymphotropic virus, HTLV) que conforma el Protocolo Clínico y Directrices Terapéuticas para la Atención Integral a Personas con Infecciones de Transmisión Sexual, publicado por el Ministerio de Salud de Brasil. La infección por HTLV-1/2 es un problema de salud pública en el mundo y Brasil tiene el mayor número de personas que viven con el virus. El HTLV-1 causa varias manifestaciones clínicas, de naturaleza neoplásica (leucemia/linfoma de células T adultas), y de naturaleza inflamatoria, como la mielopatía asociada al HTLV-1 y otras manifestaciones como la uveítis, la artritis y la dermatitis infecciosa. Estas patologías tienen una alta morbilidad y mortalidad e impactan negativamente en la calidad de vida de las personas infectadas. Esta revisión incluye información relevante para gerentes y profesionales de la salud sobre los mecanismos de transmisión viral, diagnóstico, tratamiento y monitoreo de personas que viven con HTLV-1 y 2 en Brasil.
Palavras-chave
Sexually Transmitted Diseases, Diagnosis, Signs and Symptoms, Disease Prevention, Doenças Sexualmente Transmissíveis, Diagnóstico, Sinais e Sintomas, Prevenção de Doenças, Enfermedades de Transmisión Sexual, Diagnóstico, Signos y Síntomas, Prevención de Enfermedades
URI
https://observatorio.fm.usp.br/handle/OPI/40638
Referências
  1. Abolbashari S, 2019, J BLOOD MED, V10, P29, DOI 10.2147/JBM.S184913
  2. Abrams A, 2011, VIRUSES-BASEL, V3, P1320, DOI 10.3390/v3081320
  3. ALETAHA D, 2010, BLOOD, V62, P2569, DOI 10.1002/ART.27584
  4. Ando Y, 2003, J INFECTION, V46, P9, DOI 10.1053/jinf.2002.1081
  5. Apoliano CF, 2020, AIDS RES HUM RETROV, V36, P6, DOI [10.1089/aid.2018.0290, 10.1089/AID.2018.0290]
  6. Araujo A, 2004, ANN NEUROL, V56, P10, DOI 10.1002/ana.20126
  7. Araujo Abelardo, 2021, Neurol Clin Pract, V11, P49, DOI 10.1212/CPJ.0000000000000832
  8. Araujo AQC, 2019, AIDS REV, V21, P211, DOI 10.24875/AIDSRev.19000108
  9. Araujo AQC, 2015, CURR INFECT DIS REP, V17, DOI 10.1007/s11908-014-0459-0
  10. Bahia F, 2011, JAIDS-J ACQ IMM DEF, V57, pS202, DOI 10.1097/QAI.0b013e31821e9a1e
  11. Bangham CRM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.12
  12. Rosadas C, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0170-y
  13. Rosadas C, 2014, J NEUROVIROL, V20, P636, DOI 10.1007/s13365-014-0280-4
  14. Rosadas C, 2013, J VIROL METHODS, V193, P536, DOI 10.1016/j.jviromet.2013.07.040
  15. Salles F, 2013, T ROY SOC TROP MED H, V107, P526, DOI 10.1093/trstmh/trt052
  16. Santos Jairo Vvo Dos, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P343
  17. de Oliveira MDSP, 2012, CLIN INFECT DIS, V54, P1714, DOI 10.1093/cid/cis273
  18. Satake M, 2012, J MED VIROL, V84, P327, DOI 10.1002/jmv.23181
  19. SATO K, 1991, ARTHRITIS RHEUM, V34, P714, DOI 10.1002/art.1780340612
  20. SATO Y, 1989, CLIN IMMUNOL IMMUNOP, V52, P214, DOI 10.1016/0090-1229(89)90173-6
  21. Umeki K, 2017, CLIN LAB, V63, P227, DOI 10.7754/Clin.Lab.2016.160501
  22. Ishak R, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-0512-z
  23. Boa-Sorte N, 2014, BRAZ J INFECT DIS, V18, P618, DOI 10.1016/j.bjid.2014.05.009
  24. Schierhout G, 2019, LANCET INFECT DIS, V20, P407
  25. Schierhout G, 2020, LANCET INFECT DIS, V20, P133, DOI 10.1016/S1473-3099(19)30402-5
  26. Sequeira CG, 2012, REV SOC BRAS MED TRO, V45, P453, DOI [10.1590/S0037-86822012005000007, 10.1590/s0037-86822012005000007]
  27. SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
  28. SHIMOYAMA M, 1991, LEUKEMIA RES, V15, P81
  29. Champs APS, 2010, REV SOC BRAS MED TRO, V43, P668, DOI 10.1590/S0037-86822010000600013
  30. Silva EA, 2002, J MED VIROL, V66, P253, DOI 10.1002/jmv.2138
  31. Silva MT, 2009, CLIN INFECT DIS, V48, pE34, DOI 10.1086/595855
  32. Oliveira TSS, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0486-2018
  33. Ishak R, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01663
  34. Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177
  35. Barmpas DBS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007404
  36. Starling ALB, 2015, BIOMARKERS, V20, P502, DOI 10.3109/1354750X.2015.1094141
  37. TAJIMA K, 1988, INT J CANCER, V41, P505
  38. Magalhaes T, 2008, J MED VIROL, V80, P2040, DOI 10.1002/jmv.21278
  39. Ureta-Vidal A, 1999, INT J CANCER, V82, P832, DOI 10.1002/(SICI)1097-0215(19990909)82:6<832::AID-IJC11>3.0.CO;2-P
  40. Van Dooren S, 2001, MOL BIOL EVOL, V18, P661, DOI 10.1093/oxfordjournals.molbev.a003846
  41. van Tienen C, 2019, BRIT J HAEMATOL, V184, P688, DOI 10.1111/bjh.15160
  42. Vandamme AM, 1998, J VIROL, V72, P4327, DOI 10.1128/JVI.72.5.4327-4340.1998
  43. Verdonck K, 2008, EPIDEMIOL INFECT, V136, P1076, DOI 10.1017/S0950268807009521
  44. Itabashi K, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00595
  45. VIDAL AU, 1994, AIDS RES HUM RETROV, V10, P1557, DOI 10.1089/aid.1994.10.1557
  46. Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102
  47. Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
  48. Yamauchi J, 2021, PHARMACOL THERAPEUT, V218, DOI 10.1016/j.pharmthera.2020.107669
  49. Yared JA, 2015, CANCERS, V7, P2318, DOI 10.3390/cancers7040893
  50. Falcao LFM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186055
  51. Brant LJ, 2011, EUROSURVEILLANCE, V16, P7
  52. Zihlmann KF, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001705
  53. ZUCKERFRANKLIN D, 1992, BLOOD, V80, P1537
  54. Zunt JR, 2006, AM J TROP MED HYG, V74, P922, DOI 10.4269/ajtmh.2006.74.922
  55. Jacob F, 2008, J CLIN VIROL, V42, P149, DOI 10.1016/j.jcv.2008.01.017
  56. Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015
  57. Brites C, 2020, CLIN INFECT DIS, V71, P196, DOI 10.1093/cid/ciz756
  58. Brites C, 2018, JAIDS-J ACQ IMM DEF, V77, P230, DOI 10.1097/QAI.0000000000001576
  59. Brites C, 2009, AIDS REV, V11, P8
  60. Brito VD, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00961-18
  61. Broutet N, 1996, INT J STD AIDS, V7, P365, DOI 10.1258/0956462961918103
  62. Mangano AM, 2004, J MED VIROL, V74, P323, DOI 10.1002/jmv.20172
  63. Cabral F, 2012, VIRUS RES, V163, P87, DOI 10.1016/j.virusres.2011.08.014
  64. Campos KR, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01384-19
  65. Campos KR, 2017, BRAZ J INFECT DIS, V21, P297, DOI 10.1016/j.bjid.2017.02.005
  66. Braco ILJ, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4041-0
  67. Canepa C, 2015, VIRUSES-BASEL, V7, P5643, DOI 10.3390/v7112897
  68. Carneiro-Proietti ABF, 2012, AIDS RES HUM RETROV, V28, P1265, DOI 10.1089/aid.2011.0143
  69. Cassar O, 2017, METHODS MOL BIOL, V1582, P3, DOI 10.1007/978-1-4939-6872-5_1
  70. Catalan-Soares B, 2005, AIDS RES HUM RETROV, V21, P521, DOI 10.1089/aid.2005.21.521
  71. Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P1
  72. Chew R, 2018, INT OPHTHALMOL, V38, P2159, DOI 10.1007/s10792-017-0659-3
  73. Coler-Reilly ALG, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0451-x
  74. MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609
  75. Cook LB, 2019, J CLIN ONCOL, V37, P677, DOI 10.1200/JCO.18.00501
  76. Cook LBM, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-015-0236-7
  77. Kako S, 2019, CASE REP ONCOL MED, V2019, DOI 10.1155/2019/8357893
  78. DACOSTA CA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/J0URNAL.PNTD.0002272
  79. Dantas L, 2014, INT J DERMATOL, V53, P1098, DOI 10.1111/ijd.12170
  80. Mendes MDC, 2020, BRAZ J MICROBIOL, V51, P637, DOI 10.1007/s42770-020-00233-0
  81. de Mendoza C, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4346-z
  82. de Mendoza C, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz036
  83. de Oliveira SR, 2006, REV BRAS GINECOL OBS, V28, P467, DOI 10.1590/S0100-72032006000800005
  84. de Souza VG, 2012, REV SOC BRAS MED TRO, V45, P159, DOI 10.1590/S0037-86822012000200004
  85. DEARAUJO AC, 1994, EUR J EPIDEMIOL, V10, P165, DOI 10.1007/BF01730366
  86. Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
  87. Demontis MA, 2015, J MED VIROL, V87, P2130, DOI 10.1002/jmv.24264
  88. KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847
  89. Dennis G, 2007, NAT CLIN PRACT RHEUM, V3, P675, DOI 10.1038/ncprheum0648
  90. Dias ARN, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01879
  91. Dias-Bastos MR, 2010, REV SOC BRAS MED TRO, V43, P615, DOI 10.1590/S0037-86822010000600002
  92. Duong YT, 2008, AIDS RES HUM RETROV, V24, P1503, DOI 10.1089/aid.2008.0128
  93. Einsiedel L, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3366-5
  94. Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996
  95. Dal Fabbrol MMFJ, 2008, REV SOC BRAS MED TRO, V41, P148, DOI 10.1590/S0037-86822008000200003
  96. Figueiro-Filho EA, 2007, REV SOC BRAS MED TRO, V40, P181, DOI 10.1590/S0037-86822007000200007
  97. Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870
  98. Martins ML, 2010, J MED VIROL, V82, P1746, DOI 10.1002/jmv.21881
  99. Kamihira S, 2010, CANCER SCI, V101, P2361, DOI 10.1111/j.1349-7006.2010.01720.x
  100. Gallo RC, 2005, ONCOGENE, V24, P5926, DOI 10.1038/sj.onc.1208980
  101. GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
  102. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  103. Gillet NA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003263
  104. Mello MAG, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-28
  105. Gotuzzo E, 2007, REV PANAM SALUD PUBL, V22, P223, DOI 10.1590/S1020-49892007000900001
  106. Guerra AB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1753-x
  107. HALL WW, 1992, J VIROL, V66, P2456, DOI 10.1128/JVI.66.4.2456-2463.1992
  108. HANADA S, 1989, CANCER, V64, P1290, DOI 10.1002/1097-0142(19890915)64:6<1290::AID-CNCR2820640620>3.0.CO;2-Z
  109. Hananiya H S, 2019, J Immunoassay Immunochem, V40, P485, DOI 10.1080/15321819.2019.1636817
  110. Kamoi K, 2020, BRIT J OPHTHALMOL, V104, P1647, DOI 10.1136/bjophthalmol-2019-315675
  111. Matsuda T, 2005, J CLIN ENDOCR METAB, V90, P5704, DOI 10.1210/jc.2005-0679
  112. Hayashi D, 2008, J NEUROVIROL, V14, P459, DOI 10.1080/13550280802178538
  113. Hayden RT, 2013, J CLIN MICROBIOL, V51, P540, DOI 10.1128/JCM.02620-12
  114. Haziot ME, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006967
  115. Hino S, 2011, P JPN ACAD B-PHYS, V87, P152, DOI 10.2183/pjab.87.152
  116. Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561
  117. HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7
  118. International Commitee on Taxonomy of Viruses - ICTV, 2017, TAX HIST PRIM T LYMP
  119. Ishak R, 2007, EPIDEMIOL INFECT, V135, P604, DOI 10.1017/S0950268806006984
  120. ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
  121. MAYTAL J, 1993, MT SINAI J MED, V60, P242
  122. Ishak R, 2001, Rev Soc Bras Med Trop, V34, P519, DOI 10.1590/S0037-86822001000600004
  123. Matsuzaki T, 2001, J NEUROVIROL, V7, P228
  124. Ishak R, 1998, Rev Soc Bras Med Trop, V31, P193, DOI 10.1590/S0037-86821998000200005
  125. Tajima K, 1995, INTERVIROLOGY, V38, P238, DOI 10.1159/000150438
  126. Katsuya H, 2015, BLOOD, V126, P2570, DOI 10.1182/blood-2015-03-632489
  127. KAWAI H, 1992, J MED VIROL, V38, P138, DOI 10.1002/jmv.1890380212
  128. KONDO T, 1989, INT J CANCER, V43, P1061, DOI 10.1002/ijc.2910430618
  129. Kuramitsu M, 2017, J CLIN MICROBIOL, V55, P2838, DOI 10.1128/JCM.00659-17
  130. Kuramitsu M, 2015, J CLIN MICROBIOL, V53, P3485, DOI 10.1128/JCM.01628-15
  131. La Rosa AM, 2009, CLIN INFECT DIS, V49, P112, DOI 10.1086/599609
  132. LAGRENADE L, 1990, LANCET, V336, P1345
  133. LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840
  134. Lairmore MD, 2011, VIRUSES-BASEL, V3, P1131, DOI 10.3390/v3071131
  135. Le Marchand C, 2015, BRAZ J INFECT DIS, V19, P486, DOI 10.1016/j.bjid.2015.06.007
  136. TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508
  137. Medeiros ACM, 2018, J MED VIROL, V90, P998, DOI 10.1002/jmv.25014
  138. Lee TH, 2004, J CLIN VIROL, V31, P275, DOI 10.1016/j.jcv.2004.05.016
  139. Lezin A, 2005, J INFECT DIS, V191, P1830, DOI 10.1086/429962
  140. Filho ACM, 2010, REV BRAS GINECOL OBS, V32, P176, DOI 10.1590/S0100-72032010000400005
  141. Bartholomew C, 1998, J Hum Virol, V1, P302
  142. Ministerio da Saude (BR), 2016, PROT US ZID TRAT AD
  143. Ministerio da Saude (BR). Secretaria de Vigilancia em Saude, 2013, GUIA MAN CLIN INF HT
  144. Ministerio da Saude (BR). Secretaria de Vigilancia em Saude. Departamento de Doencas de Condicoes Cronicas e Infeccoes Sexualmente Transmissiveis, 2020, PROT CLIN DIR TER AT
  145. MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124
  146. MOCHIZUKI M, 1994, BRIT J OPHTHALMOL, V78, P149, DOI 10.1136/bjo.78.2.149
  147. Tamegao-Lopes BP, 2006, REV SOC BRAS MED TRO, V39, P548, DOI 10.1590/S0037-86822006000600007
  148. Mohammadi FS, 2019, MICROB PATHOGENESIS, V134, DOI 10.1016/j.micpath.2019.103578
  149. Montanheiro P, 2008, VIRUS RES, V135, P22, DOI 10.1016/j.virusres.2008.01.015
  150. Montanheito PA, 2005, BRAZ J MED BIOL RES, V38, P1643, DOI 10.1590/S0100-879X2005001100011
  151. MONTEIRO DLM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/J0URNAL.PNTD.0003146
  152. MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
  153. Bimbi C, 2019, CLIN CASE REP, V7, P474, DOI 10.1002/ccr3.1983
  154. Morimoto Helena Kaminami, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P225, DOI 10.1590/S0036-46652007000400006
  155. Moriuchi M, 2004, J VIROL, V78, P12709, DOI 10.1128/JVI.78.22.12709-12711.2004
  156. Moura AA, 2015, INT J INFECT DIS, V39, P10, DOI 10.1016/j.ijid.2015.07.022
  157. Murphy EL, 2016, TRANSFUS CLIN BIOL, V23, P13, DOI 10.1016/j.tracli.2015.12.001
  158. Tanajura D, 2015, CLIN INFECT DIS, V61, P49, DOI 10.1093/cid/civ229
  159. MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555
  160. Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
  161. NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203
  162. Nakao K, 2018, BRIT J OPHTHALMOL, V102, P373, DOI 10.1136/bjophthalmol-2017-310658
  163. Nayar S, 2018, TRANSPL P, V50, P3940, DOI 10.1016/j.transproceed.2018.08.031
  164. NEWTON RC, 1992, AM J MED, V92, P202, DOI 10.1016/0002-9343(92)90113-P
  165. Bittencourt AL, 2010, INT J DERMATOL, V49, P1099, DOI 10.1111/j.1365-4632.2010.04568.x
  166. Nishijima T, 2019, LANCET INFECT DIS, V19, P15, DOI 10.1016/S1473-3099(18)30735-7
  167. NISHIOKA K, 1989, LANCET, V1, P441
  168. Norrgren HR, 2008, JAIDS-J ACQ IMM DEF, V48, P607, DOI 10.1097/QAI.0b013e31817efb83
  169. Taniguchi H, 2019, INT J HEMATOL, V109, P402, DOI 10.1007/s12185-019-02602-4
  170. Nosaka K, 2017, CANCER SCI, V108, P2478, DOI 10.1111/cas.13398
  171. Nozuma S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00885
  172. Nunes D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171303
  173. OHBA N, 1989, JPN J OPHTHALMOL, V33, P1
  174. Okajima R, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002546
  175. Okajima R, 2013, INT J DERMATOL, V52, P63, DOI 10.1111/j.1365-4632.2012.05606.x
  176. Oki T, 1992, Asia Oceania J Obstet Gynaecol, V18, P371
  177. Bittencourt Achiléa Lisboa, 2006, J. Pediatr. (Rio J.), V82, P411, DOI [10.2223/JPED.1573, 10.1590/S0021-75572006000800004]
  178. Okuma K, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-00534-0
  179. Olbrich Neto J., 2004, Revista da Sociedade Brasileira de Medicina Tropical, V37, P28, DOI 10.1590/S0037-86822004000100008
  180. Tebourski F, 2004, DIAGN MICR INFEC DIS, V48, P59, DOI 10.1016/j.diagmicrobio.2003.08.004
  181. Olindo S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006304
  182. OSAME M, 1986, LANCET, V1, P1031
  183. Paiva AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25939-y
  184. Pedroso C, 2011, JAIDS-J ACQ IMM DEF, V57, pS208, DOI 10.1097/QAI.0b013e31821e9baf
  185. Perzova R, 2010, AIDS RES HUM RETROV, V26, P1229, DOI 10.1089/aid.2010.0079
  186. Peters AA, 1999, J CLIN VIROL, V14, P37, DOI 10.1016/S1386-6532(99)00041-4
  187. Phillips AA, 2010, CANCER-AM CANCER SOC, V116, P3438, DOI 10.1002/cncr.25147
  188. Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81
  189. Bittencourt AL, 2001, J ACQ IMMUN DEF SYND, V26, P490, DOI 10.1097/00126334-200104150-00016
  190. POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0
  191. Terashima Angelica, 2002, International Journal of Infectious Diseases, V6, P28, DOI 10.1016/S1201-9712(02)90132-3
  192. POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
  193. Porto Maria Aurélia F., 2002, Rev. Soc. Bras. Med. Trop., V35, P641, DOI 10.1590/S0037-86822002000600016
  194. Primo J, 2009, BRAZ J MED BIOL RES, V42, P761, DOI 10.1590/S0100-879X2009005000008
  195. Puccioni-Sohler M, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0343-2019
  196. Renner JDP, 2006, AIDS RES HUM RETROV, V22, P301, DOI 10.1089/aid.2006.22.301
  197. Grassi MFR, 2013, J CLIN VIROL, V58, P584, DOI 10.1016/j.jcv.2013.09.003
  198. RODGERSJOHNSON P, 1985, LANCET, V2, P1247
  199. Rosadas C, 2020, BRIT J HAEMATOL, V188, pE46, DOI 10.1111/bjh.16318
  200. Rosadas C, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007736
  201. Black FL, 1997, HUM BIOL, V69, P467
  202. Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428
  203. Rosadas C, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00999

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - LIM/56